SCHEMBL2269478

SCHEMBL2269478

COS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.47
PRSS1 P07477 2/20 0.47
PRSS2 P07478 2/20 0.47
PRSS3 P35030 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SOS1 Q07889 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
PTGS2 P35354 2/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL777482 0.87 PKM (0.46) CA1CA2MMP1MMP2MMP9
SCHEMBL29041060 0.83 F2 (0.42) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL197570 0.80 CA12 (0.46) MEN1KMT2ACA1CA2ALDH1A1
SCHEMBL28944799 0.80 MEN1 (0.50) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL16467640 0.80 CYP1A2 (0.42) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL16467726 0.78 CYP1A2 (0.41) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL27524 0.78 GAA (0.56) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL9901122 0.78 GAA (0.56) F2PRSS1PRSS2PRSS3MEN1
SCHEMBL14779504 0.77 CA1 (0.46) F2PRSS1PRSS2PRSS3MEN1
Methanesulfonic Acid Methyl Ester SCHEMBL27792596 0.77 USP2 (0.56) F2PRSS1PRSS2PRSS3SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110635167-B Nonaqueous electrolyte solution, battery containing same, and electric vehicle 比亚迪股份有限公司 2021-04-20 CN claimed
CN-110635167-A Nonaqueous electrolyte solution, battery containing same, and electric vehicle 比亚迪股份有限公司 2019-12-31 CN claimed
US-6737550-B2 LITHIUM SALT OF 4- FLUOROPHENYL METHYL SULFONE AS THE CHEMICAL INTERMEDIATE; DRUG WITH ANTIANDROGEN ACTIVITY BIOGAL GRYOGYSZERGYAR RT. (HU) 2004-05-18 US claimed
EP-3276735-B1 NONAQUEOUS ELECTROLYTE FOR SODIUM SECONDARY BATTERY AND SODIUM SECONDARY BATTERY SUMITOMO CHEMICAL CO (JP) 2023-07-12 EP disclosed
CN-109071541-B Phenyl [ a ] indole [2,3-g ] quinolizine compound, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2021-06-18 CN disclosed
CN-110635167-B Nonaqueous electrolyte solution, battery containing same, and electric vehicle 比亚迪股份有限公司 2021-04-20 CN disclosed
CN-107431246-B Nonaqueous electrolyte for sodium secondary battery and sodium secondary battery 住友化学株式会社 2021-03-09 CN disclosed
WO-2020237169-A1 SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS OHIO STATE INNOVATION FOUNDATION (US) 2020-11-26 WO disclosed
EP-2841429-B1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2020-10-21 EP disclosed
CN-110635167-A Nonaqueous electrolyte solution, battery containing same, and electric vehicle 比亚迪股份有限公司 2019-12-31 CN disclosed
EP-2827433-B1 SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY USING SAME ENVISION AESC ENERGY DEVICES LTD (JP) 2019-09-25 EP disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 US disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 US disclosed
WO-2007041677-A9 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX INC (US) 2007-05-31 WO disclosed
WO-2007041584-A2 IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041463-A2 ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041677-A2 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041593-A2 ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof COL2A1, MMP1, FN1 F2 2448/4885PRSS1 346/4885PRSS2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.